Skip to main content
    S

    Si-Bone Inc (SIBN)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $24.24
    -0.03 (-0.12%)

    Market Cap: $1.09B

    Last updated: Nov 06, 2026 at 4:10 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    67%(22/33)
    Avg Surprise
    +10.91%
    Streak
    17 Q

    Upcoming Estimates

    Period ending Dec 31, 2026
    EPS Consensus$0.07
    Range$0.02 - $0.11
    8 analysts
    Revenue Consensus
    $70M
    Range$70M - $71M
    9 analysts
    Last 12 of 35 reported quarters and 1 upcoming estimate
    PeriodReportedEst.RangeSurpriseB/MAnalystsRevisionsYoY
    Dec 26EST
    		-$0.07$0.02 - $0.11--8--
    Sep 26
    Reported Nov 2
    		$-0.08$-0.13$-0.17 - $-0.07+38.46%Beat8
    1
    4
    30d
    		+27.3%
    Jun 26
    Reported Aug 3
    		$-0.09$-0.15$-0.17 - $-0.12+40.00%Beat8
    2
    1
    30d
    		+35.7%
    Mar 26
    Reported May 11
    		$-0.10$-0.19$-0.24 - $-0.16+47.37%Beat7
    1
    5
    30d
    		+33.3%
    Dec 25
    Reported Feb 23
    		$-0.04N/A-+69.23%Beat9
    0
    2
    30d
    		+63.6%
    Sep 25
    Reported Nov 10
    		$-0.11$-0.16$-0.20 - $-0.14+31.25%Beat8
    4
    0
    30d
    		+31.3%
    Jun 25
    Reported Aug 4
    		$-0.14$-0.18$-0.23 - $-0.15+22.22%Beat8
    6
    1
    30d
    		+36.4%
    Mar 25
    Reported May 5
    		$-0.15$-0.22$-0.27 - $-0.18+31.82%Beat8
    2
    3
    30d
    		+44.4%
    Dec 24
    Reported Feb 24
    		$-0.11$-0.13$-0.18 - $-0.01+18.09%Beat7
    0
    1
    30d
    		+59.3%
    Sep 24
    Reported Nov 12
    		$-0.16$-0.24$-0.29 - $-0.20+33.33%Beat9
    No revisions (30d)
    		+36.0%
    Jun 24
    Reported Aug 5
    		$-0.22$-0.28$-0.30 - $-0.24+21.43%Beat9
    No revisions (30d)
    		+26.7%
    Mar 24
    Reported May 6
    		$-0.27$-0.31$-0.37 - $-0.26+12.90%Beat9
    No revisions (30d)
    		+15.6%
    Dec 23
    Reported Feb 26
    		$-0.27$-0.28$-0.31 - $-0.23+3.57%Beat8
    No revisions (30d)
    		+15.6%

    Key Metrics

    Valuation
    P/E Ratio-78.19EV/EBITDAN/A
    Price/FCF-259.51xFCF Yield-0.39%
    Profitability
    Profit Margin-6.20%Operating Margin-7.81%
    ROE-7.67%ROIC-6.00%
    Financial Health
    Debt/Equity0.19xInterest Coverage-6.89x
    Current Ratio7.58xQuick Ratio6.15x
    Trading Statistics
    Beta0.62Avg Volume868.45K
    52-Week High$25.9252-Week Low$11.48

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$22.57
    SMA 20$21.43
    SMA 50$19.81
    SMA 200$16.56
    EMA 10$22.85
    EMA 20$21.79
    EMA 50$20.29
    EMA 200$17.81

    MACD

    Line: 1.22Signal: 0.90Hist: 0.32

    ADX

    ADX: 29.9+DI: 33.1-DI: 13.1

    Aroon & PSAR

    Aroon Up92.0
    Aroon DownN/A
    PSAR$19.61

    Bollinger Bands

    Upper Band$24.83
    Lower Band$18.03
    %B Position3171%(Upper)
    Band Width0.91

    RSI (14-Day)

    Neutral
    66.8

    Momentum Oscillators

    Stoch %K79.1
    Stoch %D78.4
    Williams %R-24.5
    ROC (10d)12.8%
    Momentum2.76
    CCI (20d)154.6
    MFI (14d)65.3

    Volatility Measures

    ATR (14d)$1.23(5.1%)
    StdDev (20d)1.70
    Hist Vol75.8%(High)

    Volume Flow

    VWAP$24.11
    OBV3.7M
    AD Line6.5M
    CMF (20d)0.196

    Volume Metrics

    Avg Vol (20d)889.4K
    Vol Ratio0.8x
    VWMA (20d)$22.13

    Pivot Points

    R3$26.33
    R2$25.68
    R1$24.97
    Pivot Point$24.32
    S1$23.61
    S2$22.96
    S3$22.25

    Advanced Oscillators

    TSI31.84
    Ultimate Osc60.5
    KST174.66

    Financial Data

    QuarterSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total Revenue$55.70M$56.01M$52.59M$56.35M$48.66M$48.63M$47.29M$49.00M$40.34M$39.97M$37.87M$38.86M
    Cost of Revenue$11.54M$11.46M$10.64M$11.82M$9.81M$9.82M$9.60M$10.22M$8.44M$8.39M$8.00M$10.18M
    Gross Profit$44.17M$44.55M$41.94M$44.53M$38.85M$38.81M$37.70M$38.78M$31.90M$31.58M$29.86M$28.68M
    Operating Expenses$48.52M$49.35M$47.04M$46.99M$44.23M$45.81M$45.17M$44.27M$39.54M$41.65M$41.91M$41.18M
    R&D$4.56M$5.22M$4.19M$4.36M$4.24M$4.31M$4.53M$3.87M$3.99M$4.35M$4.34M$4.16M
    SG&A$10.11M$10.11M$10.04M$9.82M$10.03M$10.72M$9.96M$9.15M$8.10M$8.33M$8.18M$8.08M
    Operating Income$-4,351,000$-4,806,000$-5,093,000$-2,463,000$-5,383,000$-7,004,000$-7,480,000$-5,494,000$-7,633,000$-10,078,000$-12,043,000$-12,506,000
    Interest Income$1.35M$1.33M$1.35M$1.45M$1.51M$1.52M$1.59M$1.78M$1.94M$2.02M$2.11M$2.23M
    Interest Expense$608,000$598,000$592,000$630,000$670,000$666,000$662,000$795,000$884,000$880,000$881,000$890,000
    Income Before Tax$-3,620,000$-4,088,000$-4,334,000$-1,672,000$-4,566,000$-6,152,000$-6,542,000$-4,495,000$-6,575,000$-8,939,000$-10,904,000$-10,983,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-3,620,000$-4,088,000$-4,334,000$-1,644,000$-4,566,000$-6,152,000$-6,542,000$-4,495,000$-6,575,000$-8,939,000$-10,904,000$-10,983,000
    EBITDA$-3,114,000$-3,629,000$-4,010,000$-1,407,000$-4,596,000$-6,432,000$-7,081,000$-5,431,000$-7,735,000$-10,497,000$-12,566,000$-12,297,000
    EBIT$-4,360,000$-4,822,000$-5,092,000$-2,463,000$-5,411,000$-7,006,000$-7,472,000$-5,484,000$-7,627,000$-10,074,000$-12,136,000$-12,321,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about SIBN

    SIBN Valuation and Fair Value

    P/E
    -78.2x
    P/FCF
    -259.5x
    P/B
    5.9x
    See GNG's fair value

    SIBN Profitability: Margins, ROIC and FCF

    Gross margin
    79.4%
    Operating margin
    -7.8%
    Net margin
    -6.2%
    ROIC
    -6.0%
    ROE
    -7.7%
    FCF margin
    -1.9%
    FCF yield
    -0.4%

    SIBN Competitors

    CompanyTicker
    Integra LifeSciences HoldingsIART
    CureVac NVCVAC
    Iradimed CoIRMD
    Castle Biosciences IncCSTL
    Verastem IncVSTM
    Ventyx Biosciences IncVTYX
    Vor Biopharma IncVOR
    QuidelOrtho CorpQDEL

    Sector: Healthcare

    SIBN Analyst Ratings

    Consensus
    Buy
    Analysts
    9
    Strong Buy
    3
    Buy
    6
    Hold
    0
    Sell
    0
    Strong Sell
    0

    SIBN Bull Case vs Bear Case

    Bull case

    • SIBN beat EPS estimates in 100.0% of its last 8 reported quarters.
    • SIBN grew quarterly revenue 14.5% year over year.
    • 100.0% of SIBN's analyst ratings are Buy or Strong Buy.

    Bear case

    • SIBN has a -6.2% net profit margin.

    SIBN Earnings: Beat Rate and Next Report

    Beat rate
    8 of 8 quarters (100.0%)
    Average surprise
    37.3%
    EPS estimate (fiscal period ending Dec 31, 2026)
    $0.07

    SIBN Earnings Call

    The latest SIBN earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    SIBN ETF Holders

    GNG tracks 10 ETFs that hold SIBN. The largest weights:

    1. State Street SPDR S&P Health Care Equipment ETF (XHE), 1.30% of the fund
    2. iShares U.S. Medical Devices ETF (IHI), 0.13% of the fund
    3. Royce Value Trust Inc (RVT), 0.07% of the fund
    4. Vanguard Russell 2000 Index Fund ETF Shares (VTWO), 0.03% of the fund
    5. iShares Russell 2000 ETF (IWM), 0.02% of the fund
    Open the ETF Stock Exposure tool for SIBN

    See insider activity

    Frequently Asked Questions About SIBN

    Does SIBN pay dividends?

    Si-Bone Inc (SIBN) does not currently pay a regular dividend.

    What is SIBN's market cap?

    Si-Bone Inc (SIBN) has a market capitalization of $1.09B with a current stock price of $24.24.

    Related stocks

    Sector: Healthcare

    All stocks starting with S

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In